Lillian Shahied Arruda

Pfizer (United States) — United States

Medicine · Health Sciences

3h-index77citations15works3.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(11), BRCA gene mutations in cancer(8), PARP inhibition in cancer therapy(7), Economic and Financial Impacts of Cancer(5), Breast Cancer Treatment Studies(3)

Publications15 total

A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Journal of Comparative Effectiveness Research·2024· 9 citedOpen Access
Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices
Future Oncology·2024· 2 citedOpen Access
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States
Frontiers in Oncology·2024Open Access
Abstract P4-07-09: Identifying Drivers of First-Line HR+/HER2- Metastatic Breast Cancer Treatment Choices
Cancer Research·2023
Abstract P2-09-08: Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline <i>BRCA1/2</i> mutation(s) (g<i>BRCA1/2</i>mut): Results from a US real-world study
Cancer Research·2022
Abstract P2-09-05: Germline <i>BRCA1/2</i> mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)
Cancer Research·2022
Abstract PS11-42: Treatment patterns and clinical outcomes among patients (pts) with HER2- advanced breast cancer (ABC) and germline <i>BRCA1/2</i> mutation(s) (g<i>BRCA1/2</i>mut): results from a US real-world study
Cancer Research·2021
Abstract PS10-53: Treatment Patterns and Clinical Outcomes Among Patients with germline BRCA1/2 mutated (<i>gBRCA1/2</i>mut) HER2+ Advanced Breast Cancer (ABC): Results from a US Real-world Study
Cancer Research·2021
Abstract PS10-36: Treatment patterns and clinical outcomes among patients (pts) with HER2- advanced breast cancer (ABC) and somatic <i>BRCA1/2</i> mutation(s) (s<i>BRCA1/2</i>mut): Results from a US real-world study
Cancer Research·2021
Treatment patterns and clinical outcomes among patients (pts) with HER2+ advanced breast cancer (ABC) and germline <i>BRCA1/2</i> mutation(s) (g<i>BRCA1/2</i>mut): Results from a US real-world study.
Journal of Clinical Oncology·2020
PCN314 REAL-WORLD PATIENT DEMOGRAPHICS, TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) AMONG HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) PATIENTS WITH BRCA1/2 MUTATIONS (BRCA1/2MUT)
Value in Health·2020· 1 cited
Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.
Journal of Clinical Oncology·2019· 1 cited
Common questions regarding clinical use of axitinib in advanced renal cell carcinoma
American Journal of Health-System Pharmacy·2014· 7 cited
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Targeted Oncology·2014· 57 citedOpen Access
Axitinib: Common questions related to real-world use of a new treatment option in advanced renal cell carcinoma.
Journal of Clinical Oncology·2014

Frequent Co-authors

Alexander Niyazov(8), Bhakti Arondekar(8), Rohan Parikh(7), Elizabeth Esterberg(7), Abigail Hitchens(7), Elias Obeid(7), Diane Lorraine Borst(2), Elizabeth A. MacLean(2), Yazdi K. Pithavala(2), James E. Morgado(2), Adam Brufsky(2), Martine C. Maculaitis(2), Lewis Kopenhafer(2), Patrick Olsen(2), Samantha K. Kurosky(2), Wendy Heck(2), Kristen Whitaker(2), Brian I. Rini(1), David I. Quinn(1), Michael Baum(1)